March 4th, 2017
•The poor understanding of the in vivo performance of nanomedicines stymies their clinical translation. Procedures to evaluate the in vivo behavior of cancer nanomedicines at systemic, tissue, single-cell, and subcellular levels in tumor-bearing immunocompetent mice are described here. This approach may help researchers to identify promising cancer nanomedicines for clinical translation.
Tags
Related Videos
Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio)
In Vivo EPR Assessment of pH, pO2, Redox Status, and Concentrations of Phosphate and Glutathione in the Tumor Microenvironment
A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
In Vitro Assay to Study Tumor-macrophage Interaction
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Copyright © 2024 MyJoVE Corporation. 판권 소유